Aquestive Therapeutics, Inc. announced the appointment of Abigail Jenkins to the company?s Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. Its?s Board of Directors will now be comprised of eight directors, seven of whom are independent directors.

Abigail ?Abbey? L. Jenkins, M.S., is President and Chief Executive Officer of Gamida Cell Ltd, a pioneer in cell therapies, and a member of the company?s Board of Directors. Ms. Jenkins brings more than 20 years of leadership experience in the biopharmaceutical industry delivering life-enhancing therapies from research to commercialization for patients in need.

Prior to joining Gamida Cell, Ms. Jenkins served as the chief commercial and business officer at Lyndra Therapeutics, Inc., a clinical-stage biopharmaceutical company, where she established and led global commercial, business development, corporate strategy and portfolio management across multiple therapeutic areas. Prior to Lyndra Therapeutics, Ms. Jenkins served as senior vice president and business unit head of vaccines at Emergent BioSolutions, Inc. where she oversaw the company?s largest therapeutic division from discovery through commercialization. Ms. Jenkins also served as chief commercial officer and U.S. business head at Aquinox Pharmaceuticals, Inc. Additionally, Ms. Jenkins has held senior commercial and business development positions at Relypsa, Inc., Actavis (now Teva Pharmaceuticals Ltd.), Pfizer and Medimmune, LLC (now AstraZeneca).

Ms. Jenkins holds a Master of Science in biotechnology and biotech business enterprise from The Johns Hopkins University, a Bachelor of Arts in psychology and biology from Indiana University, and a certificate of achievement in General Management as a Kellogg Executive Scholar. Ms. Jenkins was recognized in 2022 as one of the PharmaVoice 100, one of the industry?s 100 Most Inspiring Leaders, Disrupter Category, for change agents who define excellence in leadership in biopharma.